PVCT (Provectus Biopharmaceuticals) Insider Ownership: 8.12 % (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Provectus Biopharmaceuticals Insider Ownership?

Provectus Biopharmaceuticals PVCT -1.26% Insider Ownership is 8.12 % as of Sep. 20, 2026. The stock has 2 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Provectus Biopharmaceuticals's insider ownership is 8.12%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Provectus Biopharmaceuticals's Institutional Ownership is 0.03%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Provectus Biopharmaceuticals's Float Percentage Of Total Shares Outstanding is 92.07%.

Provectus Biopharmaceuticals Insider Ownership Historical Data

* Premium members only.

The historical data trend for Provectus Biopharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Provectus Biopharmaceuticals Insider Ownership Chart

Provectus Biopharmaceuticals Historical Data

The historical data trend for Provectus Biopharmaceuticals can be seen below:

2018-02-28 2018-03-31 2018-04-30 2018-05-31 2018-06-30 2018-07-31 2018-08-31 2018-09-30 2018-10-31 2018-11-30
Insider Ownership 8.12 8.12 8.12 8.12 8.12 8.12 8.12 8.12 8.12 8.12

Provectus Biopharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 8.12 % mean?
Provectus Biopharmaceuticals (PVCT) has a Insider Ownership of 8.12 % as of Sep. 20, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Provectus Biopharmaceuticals and its competitors.
Is Provectus Biopharmaceuticals' Insider Ownership too high?
Provectus Biopharmaceuticals' current Insider Ownership is 8.12 %.
How does Provectus Biopharmaceuticals' Insider Ownership compare to TVRD and DYAI?
Provectus Biopharmaceuticals' Insider Ownership of 8.12 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Provectus Biopharmaceuticals and its competitors. Provectus Biopharmaceuticals's current Insider Ownership is 8.12 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Provectus Biopharmaceuticals stock overvalued right now?
Provectus Biopharmaceuticals (PVCT) has a current Insider Ownership of 8.12 %. The current Insider Ownership is 8.12 %. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Provectus Biopharmaceuticals (PVCT), the current Insider Ownership is 8.12 % as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Provectus Biopharmaceuticals Business Description

Address 800 South Gay Street, Suite 1610, Knoxville, TN, USA, 37929
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (HXs). Its flagship HX molecule is named rose bengal sodium (RBS). The company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. It has one operating and reporting segment, namely, the development of immunotherapy medicines.